Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up to $4.08

Autolus Therapeutics plc (NASDAQ:AUTL) gapped up before the market opened on Monday . The stock had previously closed at $4.08, but opened at $4.23. Autolus Therapeutics shares last traded at $3.91, with a volume of 289,854 shares trading hands.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Needham & Company LLC reiterated a “buy” rating and issued a $9.00 target price on shares of Autolus Therapeutics in a research report on Monday, June 17th. William Blair reissued an “outperform” rating on shares of Autolus Therapeutics in a report on Monday, June 3rd. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, Autolus Therapeutics has an average rating of “Moderate Buy” and an average price target of $8.70.

Autolus Therapeutics Price Performance

The business’s 50 day simple moving average is $4.10 and its 200-day simple moving average is $4.43. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -3.20 and a beta of 2.05. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.55 and a current ratio of 18.55.

Autolus Therapeutics (NASDAQ:AUTL) last posted its earnings results on Thursday, August 8th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). Research analysts anticipate that Autolus Therapeutics plc will post -0.84 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Victory Capital Management Inc. bought a new position in Autolus Therapeutics during the 4th quarter valued at $768,000. Capstone Investment Advisors LLC acquired a new position in Autolus Therapeutics during the fourth quarter worth about $322,000. Bellevue Group AG bought a new stake in Autolus Therapeutics in the fourth quarter worth about $322,000. Sierra Summit Advisors LLC acquired a new stake in Autolus Therapeutics in the 4th quarter valued at about $275,000. Finally, Perceptive Advisors LLC acquired a new stake in Autolus Therapeutics in the 4th quarter valued at about $11,793,000. Institutional investors and hedge funds own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.